Viridian Therapeutics, Inc.
VRDN · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $70.8M | $300K | +23,517% |
| Operating income | −$363M | −$299M | −21.5% |
| Net income | −$343M | −$270M | −26.9% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $25.8M | $70.6M | −63.5% |
| Operating income | −$104M | −$40.0M | −159% |
| Net income | −$101M | −$34.6M | −192% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Viridian's revenue in FY2025?
- $70.8M in FY2025 (Fiscal year ended Dec 31, 2025), +23,517% vs $300K a year earlier, per its 10-K filed Feb 2026.
- Was Viridian profitable in FY2025?
- No: net income was −$343M and operating income −$363M in FY2025.
- What was Viridian's revenue in Q3 2026?
- $25.8M (−63.5% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.